Ocugen (FRA:2H51) Valuation Rank


FRA:2H51 Ocugen Inc FRA:2H51
19 GF Score
Price €1.26
GF Value €0.69
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ocugen Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ocugen Valuation Rank Related Terms

FRA:2H51
19GF Score
Ocugen Inc FRA:2H51
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ocugen (FRA:2H51) Overvalued in 2026?

Based on GuruFocus' analysis, Ocugen stock appears to be overvalued. The current stock price of €1.26 is trading 82% above its estimated GF Value™ of €0.69. GuruFocus considers Ocugen to be Significantly Overvalued.

Key valuation signals for FRA:2H51:

  • Valuation Rank:
  • GF Value™: €0.69 vs. price of €1.26 (82% above fair value)
  • GF Score™: 19/100 with 4 warning signs

No single metric tells the full story. See the FRA:2H51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocugen Business Description

Address 11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
19GF Score

Get the complete analysis for FRA:2H51

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.26
Price
€0.69
GF Value